Karyopharm Therapeutics Inc.

NASDAQ:KPTI

Biotechnology

Healthcare
$7.01 -3.62%

-$0.34 today

Market cap
$158.87M
Beta
0.82
P/E (TTM)
-1.0
EPS (TTM)
-$8.86
52W Low $3.65High $10.99

Volume 0.67M

Average 0.85M

Income Statement

Follow revenue through to earnings.

Revenue

$146.07M

FY 2025 · Annual

+0.6% YoY

Operating Income

-$90.71M

FY 2025 · Annual

Net Income

-$196.04M

FY 2025 · Annual

Income Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Revenue209.82M157.07M146.03M145.24M146.07M
Cost of Revenue3.4M5.21M4.94M6.01M5.95M
Gross Profit206.42M151.86M141.09M139.23M140.12M
Gross Margin98.4%96.7%96.6%95.9%95.9%
Research & Development160.84M148.66M138.75M143.23M125.62M
Selling, General & Admin143.85M145.4M131.88M115.44M105.21M
Operating Expenses304.69M294.06M270.63M258.67M230.83M
Depreciation & Amortization789K621K530K340K296K
EBITDA(96.99M)(139.31M)(118.42M)(38.6M)(149.85M)
EBITDA Margin-46.2%-88.7%-81.1%-26.6%-102.6%
Operating Income(98.27M)(142.2M)(129.54M)(119.44M)(90.71M)
Operating Margin-46.8%-90.5%-88.7%-82.2%-62.1%
Interest Income582K2.36M10.94M7.4M2.77M
Interest Expense26.05M25M23.82M37.42M45.85M
Other Income / Expenses(25.55M)(22.72M)(13.24M)43.08M(105.29M)
Income Before Tax(123.82M)(164.92M)(142.78M)(76.37M)(196M)
Pre-Tax Margin-59.0%-105.0%-97.8%-52.6%-134.2%
Income Tax Expense268K369K323K57K43K
Net Income(124.09M)(165.29M)(143.1M)(76.42M)(196.04M)
Net Margin-59.1%-105.2%-98.0%-52.6%-134.2%
EPS (Basic)(24.75)(30.28)(18.79)(9.41)(17.93)
EPS (Diluted)(24.75)(30.28)(18.79)(9.41)(17.93)
Weighted Avg Shares5.01M5.46M7.61M8.12M10.94M
Weighted Avg Shares (Diluted)5.01M5.46M7.61M8.12M10.94M

KPTI Earnings Waterfall · TTM

NASDAQ:KPTI · Revenue to Net Income

Key Ratios

EPS$-15.07
Gross Margin96.1%
Net Margin-134.3%
P/E Ratio-0.6
P/S Ratio2.4

Analysis

$151.1M of revenue converted into -$195.0M of net income for the selected period. Gross margin is 96.1% and net margin is -134.3%, showing how much revenue survives after costs and taxes. EPS is $-15.07, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportJul 17, 2026
SC 13G/ASC 13G/A filingJun 5, 2026
8-KCurrent reportMay 28, 2026
S-8S-8 filingMay 27, 2026
S-8S-8 filingMay 27, 2026

How much revenue does KPTI generate?

Karyopharm Therapeutics Inc. (KPTI) reported $146.07M of revenue in fiscal 2025.

Is KPTI profitable?

Karyopharm Therapeutics Inc. (KPTI) reported -$196.04M of net income, with a net margin of -134.2%.